Lexicon shareholders approve reverse stock split authorization (1:10-1:50) and increase equity plan share reserves

LEXICON PHARMACEUTICALS, INC.

• Shareholders approved reverse stock split at ratio 1-for-10 to 1-for-50, at board discretion before 2026 annual meeting.
• Equity incentive plan shares increased from 55M to 75M; Non-Employee Directors plan from 2M to 4M.
• Directors Raymond Debbane and Ivan H. Cheung elected with >205M and >226M votes for, respectively.
• Ernst & Young ratified as independent auditor for FY 2025.
• Advisory vote on executive compensation approved with 220.5M for, 7.9M against.